Press Releases

Indivior to Announce Q1 2022 Results and Host Webcast on April 28th


Slough, UK, and Richmond, VA, April 7, 2022 Indivior PLC (LON: INDV) today announced that it will release its Q1 2022 results on April 28th at 12:00 GMT (7:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's website at

Mark Crossley, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 13:00 GMT (8:00 a.m. U.S. Eastern) on April 28th.

Access to the Live Webcast Presentation
The webcast event and materials can be accessed on the "Investors" section of the company's website at before the event begins.

The webcast link is

Participants may access the presentation telephonically:

  • US participants 1-646-741-3167
  • International participants +44 (0) 2071-928338


Please reference confirmation ID 6687840. A replay of the presentation will be available at

About Indivior
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit to learn more. Connect with Indivior on LinkedIn by visiting



Jason Thompson

Vice President, Investor Relations

Tel: 804-402-7123 or


Tim Owens

Director, Investor Relations

Tel: 804-263-3978 or